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Summary We investigated the efficacy and toxicity of induction chemotherapy with cisplatin and etoposide with either bleomycin or ifosfamide in
patients with intermediate-prognosis testicular non-seminoma. A total of 84 eligible patients were randomized to receive fourcycles of etoposide,
ifosfamide, cisplatin (VIP), or four cycles of bleomycin, etoposide, cisplatin (BEP). Intermediate prognosis was defined as any of the following:
lymph node metastases 5-10 cm in diameter, lung metastases more than four in number or > 3 cm, HCG 5000-50 000 IU I-1, AFP > 1000 IU I-'.
The complete response (CR) rates to VIP and BEP were similar, 74% and 79% respectively (P = 0.62). Including the cases in whom viable
cancer was completely resected with post-chemotherapy debulking surgery, the percentages of patients who achieved a no-evidence-of-disease
status were 80% on VIP and 82% on BEP (P= 0.99). In addition, there were no differences in relapse rate, disease-free and overall survival after
a median follow-up of 7.7 years. The 5-year progression-free survival was 85% (95% Cl 74-96%) in the VIP arm and 83% (95% Cl 71-96%) in
the BEP arm, hazard ratio (VIP/BEP) 0.83 (95% Cl 0.30-2.28). The VIP regimen was more toxic with regard to bone marrow function; the
frequency of leucocytes below 2000 ,ul-1 throughout four cycles was 89% on VIP and 37% on BEP (P< 0.001). Our study does not indicate that
ifosfamide is superior to bleomycin in combination with cisplatin and etoposide. The sample size in this study is small as the study was
prematurely discontinued when data became available from a competing study that showed no improved effectiveness of VIP compared with
BEP. Taken together with these data, bleomycin should not be replaced by conventional-dose ifosfamide.
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The treatment of metastatic germ cell tumours with modem
cisplatin-based chemotherapy results in cure in approximately
70-80% of patients (Einhorn et al, 1981; Einhorn et al, 1990).
Factors associated with treatment failure have been analysed in
several large studies and include large tumour volume, the pres-
ence of liver, bone or brain metastases, grossly elevated tumour
markers and an extragonadal primary site, particularly in the medi-
astinum (Einhorn et al, 1980; Bajorin et al, 1988; Mead et al,
1992). Based on these prognostic factors, during the past decade,
clinical trials have attempted to decrease the toxicity of the
standard of four bleomycin, etoposide, cisplatin (BEP) cycles in
patients with good-risk disease, or to improve the results by inten-
sifying therapy or by the incorporation of new agents in the
chemotherapeutic regimen in patients with one or more adverse
risk factors. After the demonstration of the effectiveness of ifos-
famide in germ cell cancer and reports on long-term survival of
cisplatin-ifosfamide-based salvage regimens (Loehrer et al, 1988;
Motzer et al, 1990; Munshi et al, 1990; McCaffrey et al, 1997), the
Eastern Cooperative Oncology Group (ECOG) and the European
Organization for Research and Treatment of Cancer (EORTC)
simultaneously began trials testing the substitution of ifosfamide
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for bleomycin in the induction regimen in patients with adverse
prognostic features. Here, we report the results of the randomized
study of four cycles of induction chemotherapy comparing BEP
with cycles comprising cisplatin, ifosfamide and etoposide (VIP),
conducted by the EORTC in patients with intermediate-prognosis
disease. The definition of intermediate prognosis was derived
from the preceding EORTC multivariate prognostic factor analysis
(Stoter et al, 1987).
MATERIALS AND METHODS
Patients were eligible for the study ifthey had metastatic testicular
non-seminoma with any of the following characteristics: lymph
node metastases 5-10 cm, lung metastases more than four in
number or > 3 cm, HCG 5000-50 000 IU 1-' or AFP > 1000 IU 1-'.
Patients with extragonadal primary tumours or metastatic sites
other than lymph nodes and lung (liver, bone, brain, etc.) were
excluded as they were considered to have a poor prognosis. Other
ineligibility criteria were pure seminoma (unless accompanied by
elevated HCG levels > 200 IU 1-' or elevated AFP levels), prior
radiotherapy or chemotherapy, white blood count (WBC) below
2000 ,ltl', platelet count below 100 000 ul-' or a creatinine
clearance below 40 ml min-'.
Patients were randomized to receive four cycles of BEP or four
cycles of VIP. BEP consisted ofcisplatin 20 mg m-2 intravenously
(i.v.) on days 1-5 every 3 weeks; etoposide 120 mg m-) i.v. on day
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Table 1 Relative dose intensity
BEP (n = 38) VIP (n = 46) P-valueb
Relative dose intensitya n (%) n (%)
Cisplatin (%)
70-90 1 (3) 8 (17) 0.095
90-110 37 (97) 38 (83)
Etoposide (0)
< 70 2 (5) 16 (35) < 0.001
70-90 12 (31) 20 (44)
90-100 24 (63) 10 (22)
Bleomycin (0)
< 90 6 (16)
90-100 32 (84)
Ifosfamide (0)
< 70 19 (41)
70-90 16 (35)
90-100 11 (24)
aNumbers and percentages of patients with a dose intensity relative to the
planned protocol dose intensity. bWilcoxon rank-sum test.
1, 3 and 5 every 3 weeks; and bleomycine 30 mg i.v. on day 1,
weekly for 12 weeks. The VIP schedule was the same concerning
the schedule and dose of cisplatin and etoposide; ifosfamide was
given at 1.2 g m-2 i.v. on days 1-5 every 3 weeks. Before the
infusion of ifosfamide, a bolus of mesna 200 mg m-2 was given,
followed by ifosfamide as a 4-h infusion in combination with
mesna at a dose of600 mg m-2. After completion ofifosfamide, an
additional dose of mesna 400 mg m-2was administered over the
next 4 h.
Ifat the start ofa treatment cycle the WBC was below 1500 ul-'
or platelets below 50 000 ,ul-', treatment was delayed. Blood
counts were then repeated every 3 days until these thresholds were
reached and retreatment was given. Doses of etoposide and ifos-
famide were reduced by 25% were made if the total WBC was
between 2000 and 3000 ,ul-', and by 50% if the total WBC was
between 1500 and 2000,l- or if the platelet count was between
50 000 and 100 000 p1-'.
Cisplatin, bleomycin and ifosfamide were withheld ifthe creati-
nine clearance fell below 40 ml min-m. If renal function recovered,
cisplatin was resumed at 75% and bleomycin and ifosfamide at
I00%. Severe skin toxicity and signs oflung toxicity were reasons
for termination ofbleomycin.
After fourcycles, patients with normal levels oftumour markers
and no clinical or radiological evidence of any residual lesions
were classified as complete responders and were monitored
without further therapy.
Patients in whom markers were normalized, but who showed
evidence of residual tumour mass, underwent explorative surgery.
The protocol required complete macroscopic resection of all
tumour remnants. Those patients were classified as complete
responders if the histological examination showed no viable
cancer cells. If viable malignancy was found, and it was consid-
ered that it had been resected completely, the patients were classi-
fied as having been rendered disease free by chemotherapy plus
post-chemotherapy surgery. In these cases, the protocol advised
two additional cycles of the protocol chemotherapy. Patients in
whom the surgical resection of residual disease was incomplete in
the presence of viable cancer, and/or those who had continuing
Table 2 Haematological toxicity
BEP VIP
Toxicity n (%) n (%) pa
Leucocytes (WHO grade)b
0 0 (0) 1 (2)
1 3 (8) 1 (2)
2 21 (55) 3 (7)
3 11 (29) 29 (63)
4 3 (8) 12 (26) < 0.001
Thrombocytes (WHO grade)
0 23 (61) 14 (30)
1 5 (13) 6 (13)
2 4 (11) 13 (28)
3 5 (13) 7 (15)
4 1 (3) 6 (13) 0.20
Blood culture-proven sepsis 0 (0) 1 (2)
Leucocytopenic fever 3 (8) 5 (11)
(WBC < 2000 ,ul-1, T > 38°C)
aP-values reflect comparisons of grade 3/4 toxicity between the two study
arms. bDenotes World Health Organization grade.
Table 3 Post-chemotherapy surgery
BEP (n = 38) VIP (n = 46)
Variable n (%) n (%)
Surgery performed 28 (74) 30 (65)
Complete macroscopic resection 23 (61) 27 (59)
Partial macroscopic resection 5 (13) 3 (7)
Histological findings
Viable cancer 5 (13) 4 (9)
Mature teratoma 11 (29) 16 (35)
Necrosis/fibrosis only 9 (24) 10 (22)
Unspecified 3 (8) 0 (0)
elevation of tumour markers, and/or those who had disease
progression while on chemotherapy, were classified as incomplete
responders. Rising tumour markers or an increase in tumour
volume were considered to indicate disease progression.
Response rates to the treatment regimens were compared using
the two-sided Fisher exact test (Agresti, 1990). The same test was
used for comparing the frequencies ofgrade 3/4 toxicity. The dose
intensities achieved on the two arms were compared using the
Wilcoxon rank-sum test (Lehmann, 1975). Survival and time to
progression curves were estimated using the Kaplan-Meier tech-
nique and compared with a two-sided log-rank test (Kalbfleisch
and Prentice, 1980). A significance level of0.05 was used.
The randomization was stratified by institute. Approval of the
ethics committee of the participating hospitals was obtained. All
patients gave informed consent.
RESULTS
Between September 1987 and June 1990, 87 patients were entered,
of whom 41 were randomized to BEP and 46 to VIP. Three
patients on BEP (7%) were ineligible: one was because of pure
seminoma histology, one had no testicular cancer, and one had a
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Table 4 Treatment results
BEP (n=38) VIP (n=46)
Variable n (%) n (%) pa
Response rate (all eligible patients)
Complete response
After chemotherapy 30 (79) 34 (74) 0.62
After chemotherapy and debulking surgery 1 (3) 3 (7)
Total of patients rendered disease free 31 (82) 37 (80) 0.99
Incomplete response/progression 6 (16) 4 (9)
Early death due to malignant disease 0 (0) 1 (2)
Insufficient data to evaluate responseb 0 (0) 3 (7)
Progression status (all eligible patients)
Progression during chemotherapy 1 (3) 2 (4)
Relapse 7 (18) 5 (11)
Treatment failure 8 (21) 7 (15)
Progression-free survival and survival (intent to treat) (n = 41) (n = 46)
Time to progression, events 8 (20) 7 (15) 0.72
Deaths 2 (5) 1 (2)
aLog-rank test. bPatients with residual lesions not surgically evaluated.
HCG value at entry of 459 000 IU 1-'. Out of the 84 eligible
patients, three patients on VIP were not evaluable for response as a
result of omitted explorative surgery. The analysis is based on all
eligible patients. However, all randomized patients were included
in the progression-free survival and survival analyses.
Patient characteristics
Patient characteristics (age, histology, stage, markers) were well
balanced between the two treatment groups (data not shown).
Overall, 50% of the patients had retroperitoneal lymph node
metastases only, 6% had mediastinal and/or supraclavicular lymph
node metastases, and 43% had pulmonary metastases. According
to the current risk classification (IGCCCG, 1996) 15 (40%) of the
patients on BEP fulfilled the criteria for intermediate-prognosis
disease, nine (24%) qualified for poor-prognosis disease, while
nine patients (24%) had good-prognosis disease. On the VIP arm,
these numbers were: intermediate prognosis 18 (39%); poor prog-
nosis eight (17%); good prognosis 15 (33%). From five patients on
each arm, data were lacking, predominantly LDH values at entry,
to properly classify patients according to the international criteria.
Treatment administered
All but one patient on VIP had four cycles of treatment. This
patient died ofmassive pulmonary embolism 10 days after the start
of the first cycle ofchemotherapy.
The relative dose intensity of the agents over all cycles is listed
in Table 1. The total doses per m2 delivered over all cycles and the
relative dose intensity of etoposide were less in the VIP arm than
in the BEP arm (P < 0.001). A similar, but non-significant trend
was seen in the relative dose intensity of cisplatin (P = 0.095).
Toxicity
The haematological toxicity throughout the four cycles is
presented in Table 2. The frequency of leucocytes grade 3 and/or 4
toxicity was significantly higher in the VIP arm (P < 0.001). There
was slightly more thrombocytopenia grade 3 and/or 4 in the VIP
arm, but the difference was not significant (P = 0.20). Three
patients on BEP and five patients on VIP had leucocytopenic fever
during the course oftheir treatment (P = 0.71). One patient on VIP
developed a sepsis. Pulmonary function tests were performed in 32
patients on BEP and in 33 patients on VIP. The carbon monoxide
diffusion capacity declined by a median of 14% from the baseline
value in the patients on BEP, whereas there was no decline in the
patients on VIP. Out ofall 38 patients treated with BEP, four devel-
oped clinical symptoms of pulmonary toxicity; two cases had
grade 1 (5%), one case grade 2 (3%) and one case grade 3 (3%)
toxicity. There were no other differences in non-haematological
toxicities between the two treatment arms (data not shown).
Surgery
Post-chemotherapy surgery was performed in 58 patients: 28
patients treated with BEP and 30 with VIP (Table 3). Histological
findings were essentially the same for the two treatment groups.
Overall, viable cancer was found in 16% of the surgical speci-
mens, mature teratoma in 47% and necrosis/fibrosis only in 33%
(unspecified 4%).
Response
Responses to chemotherapy are listed in Table 4. Ofthe 38 patients
on BEP, 30 (79%) achieved a complete response to chemotherapy
alone. In the VIP arm, 34 of 46 (74%) achieved a complete
response. This result is not significantly different (P = 0.62). In
addition, one patient on BEP (3%) and three patients on VIP (7%)
had viable cancer completely resected at surgery. Therefore, the
numbers of patients who were rendered disease free (NED) after
chemotherapy plus post-chemotherapy surgery were 31 (82%) on
BEP and 37 (80%) on VIP. Again, there was no difference between
the two arms (P = 0.99).
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Figure 1 Progression-free survival
Progression-free survival
After a median follow-up duration of 7.7 years, seven patients
(18%) on BEP and five (1I%) on VIP relapsed (Table 4). Of these
relapses, three (two on BEP and one on VIP) had occurred in the
nine patients who had viable cancer detected at post-chemotherapy
surgery. Including the patients who progressed during induction
chemotherapy, a total of eight patients (20%) treated with BEP,
and seven (15%) patients treated with VIP developed treatment
failure (P = 0.72). The hazard ratio (VIP/BEP) was 0.83 (95% CI
0.30-2.28). At 5 years, there was 83% progression-free survival
(95% CI 71-96%) in the BEP arm and 85% (95% CI 74-96%) in
the VIP arm. Figure 1 shows the progression-free survival for all
patients.
In the BEP arm, two patients died of malignant disease; on the
VIP arm, one patient died of massive pulmonary embolism 10
days after the start of the chemotherapy. During follow-up, no
patients developed a secondary malignancy.
DISCUSSION
We investigated the efficacy and toxicity of induction
chemotherapy with cisplatin and etoposide with either bleomycin
or ifosfamide. Four cycles of VIP were compared with the stan-
dard offour cycles of BEP with 360 mg m-2 ofetoposide per cycle.
The study began in 1987. During the course of the study, data
became available from ECOG showing no improved effectiveness
of VIP compared with BEP with 500 mg m-2 of etoposide per
cycle in a study in 304 patients with advanced stage (= poor prog-
nosis) germ cell cancer, according to Indiana criteria (Loehrer et
al, 1993). At that time, 87 patients had been entered into the study
presented here. In view ofthe outcome reported by ECOG and our
data pointing in the same direction, i.e. no indication of improved
efficacy, but increased toxicity by VIP, it was decided to close
the study.
The final report from the ECOG study with a median follow-up
of 5 years showed that 63% of the VIP-treated patients and 60% of
the BEP-treated patients remained free of disease (Nichols et al,
1998) in our study reported here, we observed a 5-year progression-
free survival of 83% with BEP and 85% with VIP. The fact that
these progression-free survival rates are higher than in the ECOG
study is explained by the fact that we selected a more favourable
prognostic category of patients. This may also be indicated by the
high salvage rate in our relapsing patients, resulting in no more than
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two disease-related deaths. Although there were no treatment-
related deaths in our study, there was significantly greater myelo-
toxicity associated with VIP. WHO grade 3 and/or 4
leucocytopenia at any time during the course ofthe four cycles was
observed in no more than 37% of patients treated with BEP
compared with 89% of patients on VIP (P < 0.001). Of note, both
treatment arrms included etoposide at a dose of 360 mg m-2 per
cycle, which was used by EORTC during that period.
When we take the results ofthe ECOG and EORTC together, we
conclude that there is no role for this dose of ifosfamide in the
induction chemotherapy regimen in non-seminomatous germ cell
cancer. Further evidence of the lack of increased efficacy of VIP
over BEP was recently obtained in a collaborative study of the
Medical Research Council (MRC) and EORTC that compared
three closely spaced cycles of bleomycin, vincristine and cisplatin
(BOP) followed by three cycles ofVIP, vs four cycles of BEP plus
two cycles of EP, in patients with poor-prognosis disease (Kaye
et al, 1998). In that study, complete response rates to BEP/EP
and BOP/VIP were 57% and 54% respectively (P = 0.69).
Progression-free survival rates for BEP/EP and BOP/VIP were
60% and 53% respectively.
Recent data have shown that the doses of both ifosfamide and
etoposide can be increased two to three times during multiple
cycles ofchemotherapy, when bone marrow support is realized by
repetitive administration of autologous blood progenitor cells
(Bokemeijer et al, 1996). In view of the substantially increased
dose intensity of these two agents, there appears a rationale to
investigate whether the use of high-dose VIP plus autologous
progenitor cell support after each cycle ofchemotherapy can result
in an improved disease-free survival in patients with poor-
prognosis disease according to the current international classifica-
tion, which shows that these patients have less than 50% survival
rate with conventional cisplatin combination chemotherapy
(IGCCCG, 1996).
We conclude that the combination of cisplatin, etoposide and
bleomycin remains the standard induction chemotherapy and that
ifosfamide should not replace bleomycin.
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